Clinical safety of oral licomycin treatment in Nile tilapia (Oreochromis niloticus) / Segurança clínica do tratamento via oral com lincomicina em tilapias (Oreochromis niloticus)

Lincomycin is a broad-spectrum antimicrobial acting against Gram-positive bacteria, widely used in veterinary medicine. In fish, there are only limited in vitro data, thus requiring the design of effective therapeutic protocols for their use in aquatic organisms. In this context, the objective was to evaluate the clinical safety of lincomycin treatment, administered orally in tilapia, through hematological, biochemical and somatic index evaluation. A total of 136 tilapia (+100g) were randomly distributed in 17 tanks (100L of water, n=8) to constitute the following treatments: TO (control group, not treated with lincomycin); T1, T2, T3 (treated with 10, 20 and 40mg/kg¹ of lincomycin b.w., respectively) and T4 physiological standard (reference values). Eight animals were sampled per treatment in 4 periods: 2, 4 and 8 days post-treatment (DPT), and a group that was treated for 8 days with the drug and then treated only with commercial feed until the 12th day (recovery period). Tilapia treated with lincomycin had no difference in the hematological and leukocyte evaluation, in the hepatic, renal and splenic somatic index. However, they presented a transient increase in the values of ALT, AST, cholesterol, triglycerides and creatinine, which returned to normal levels after the period of recovery (12DPT). Furthermore, an increase in total protein, albumin and globulin levels was observed in treated animals. It is concluded that although there were some transient changes during the experiment, lincomycin has a good clinical safety margin at doses of 10, 20 and 40mg/Kg¹ b.w. for Nile tilapia.

A lincomicina é um antimicrobiano de amplo espectro atuando contra bactérias gram-positivas, amplamente utilizada na medicina veterinária. Em peixes existem apenas dados limitados in-vitro, necessitando assim, de delineamento de protocolos terapêuticos eficazes para seu uso em organismos aquáticos. Desse modo, objetivou-se avaliar a segurança clínica do tratamento com lincomicina, administrada por via oral em tilápias, por meio da avaliação hematológica, bioquímica e indice somático hepático, renal e esplênico. Foram utilizadas 136 tilápias (±100g), distribuídas aleatoriamente em 17 tanques (100L de água, n=8) para constituir as repetições dos diferentes tratamentos: TO (grupo controle, não tratado com lincomicina); T1, T2, T3 (tratados com 10, 20 e 40mg/kg de p.v. de lincomicina, respectivamente) e T4 padrão fisiológico (valores de referência). Oito animais foram amostrados por tratamento em 4 períodos: 2, 4 e 8 dias pós-tratamento (DPT) com lincomicina, e um grupo que foi tratado por 8 dias com o fármaco e após isso tratado apenas com ração comercial até o 12º dia (período de recuperação). Tilápias tratadas com lincomicina não tiveram diferença na avaliação hematológica e leucocitária, no índice somático hepático, renal e esplênico, entretanto, apresentaram um aumento transitório nos valores de ALT, AST, colesterol, triglicérides e creatinina, que retornaram aos níveis normais após o período de recuperação (12DPT). Ademais, foram observados um incremento nos níveis de proteína total, albumina e globulina nos animais tratados. Conclui-se que embora tenha ocorrido algumas alterações transitórias ao decorrer do experimento, a lincomicina apresenta boa margem de segurança clinica nas doses de 10, 20 e 40mg/Kg¹ p.v para tilápia do Nilo.

Clinical safety of treatment with Zileuton, 5-Lox inhibitor, during acute inflammatory reaction in Nile Tilapia (Oreochromis niloticus) / Segurança clínica do tratamento com Zileuton, inibidor 5-Lox, durante reação inflamatória aguda em Tilápia do Nilo (Oreochromis niloticus)

Zileuton is an inhibitor of the 5-lipoxygenase enzyme that transforms essential fatty acid (EFA) substrates into leukotrienes (LTB4, LTC4, LTD4 and LTE4), but little is known about the use of this drug in teleost fish. Therefore, the objective of this study was to evaluate the clinical safety of treatments with 2,25 mg and 4,50 mg of zileuton/Kg-1 (bodyweight), administered orally in the diet, through biochemical and hematological analysis during the acute inflammatory reaction in Nile tilapia (Oreochromis niloticus), induced by Aeromonas hydrophila bacterins. The study used eighty tilapias, conditioned in 20 tanks (n=4), constituting the following treatments: T0 (control), T1 (2,25 mg zileuton) and T2 (4,50 mg zileuton), being sampled eight animals per treatment in three periods: 6, 24 and 48 hours post-inoculation, and a 10th group consisting of fish without any type of stimulus to obtain the reference values. In order to evaluate and determine the blood count and serum biochemical, it was necessary to collect blood samples. The hematology results of the tilapia treated with zileuton did not reveal alterations between tilapia subjected to different treatments and control fish (T0). The liver cytotoxicity analysis of tilapias treated with zileuton did not reveal significant (p≥0,05) alterations in AST and ALT serum enzymatic activity. The study of tilapia blood total protein showed decrease in the T1 group at 48 HPI. As the treatment time progressed, the results indicated decrease in the serum albumin levels for T2 group at 24 HPI. The determination of serum biochemichal of creatinine, cholesterol, triglycerides, and glucose did not differ statistically between treatments. The results observed in the hematological and biochemical analyzes allows to conclude that zileuton administered orally, at doses of 2,25 and 4,50 mg/Kg-1 (body weight) demonstrated to be clinically safe.(AU)

Safety of oral doxycycline treatment in Nile tilapia, Oreochromis niloticus / Segurança do tratamento oral com doxiciclina em tilapia do Nilo, Oreochromis niloticus

This study aimed to evaluate the clinical safety of doxycycline treatment (Sandoz Pharmacetical Industry from Brazil Ltd.), administered orally incorporated into the feed of Nile tilapia, Oreochromis niloticus. For this purpose, 75 Nile tilapia (±300g) from the same spawning were randomly distributed in 15 tanks (n=5), containing 100 L of water each, supplied with running water free from chlorine, to establish the following treatments: TO (Control - not treated with doxycycline); T1, T2, T3 and T4 (treated with 10, 20, 40 and 80mg of doxycycline/kg of body weight, respectively), in which 5 animals per treatment were sampled in 3 periods: 2, 4 and 8 days post-treatment (DPT). Blood samples were collected for hemogram determination and serum biochemical evaluation, as well as spleen, liver and kidneys (cranial and caudal) for somatic and histopathological evaluation. The results showed no significant difference among treatments in the serum values of creatinine, total protein, cholesterol, triglycerides, globulin, glycemia and alkaline phosphatase enzyme activity. However, serum levels of AST (aspartate aminotransferase) were significantly higher (P<0.05) in animals treated with 80 mg of doxycycline in the longest period of treatment (8 days). In the hematological evaluation of tilapia treated with doxycycline, no significant changes (P>0.05) were observed in erythrocyte counts, hematocrit, MCV, HCM and CHCM values. Doxycycline-treated tilapia did not present significant difference in the somatic analysis of spleen, liver and kidney when compared to control group. Therefore, the results demonstrated the clinical safety of oral treatment with doxycycline at doses of 10, 20, 40 and 80 mg/kg of b.w., although transient changes in liver functionality were observed after eight days of treatment with the dose of 80mg/kg.

Este estudo teve por objetivo avaliar a segurança clínica do tratamento com doxiciclina (Sandoz do Brasil Indústria Farmacêutica Ltda.), administrada via oral incorporada à ração em tilápias do Nilo, Oreochromis niloticus. Para tal, foram utilizadas 75 tilápias no Nilo (±300g) oriundas da mesma desova foram distribuídas aleatoriamente em 15 tanques (n=5), contendo 100 L de água cada, abastecidos com água corrente desprovida de cloro, para constituir os seguintes tratamentos: TO (Controle - não tratado com doxiciclina); T1, T2, T3 e T4 (tratados com 10, 20, 40 e 80mg de doxiciclina/kg de p.v., respectivamente. 5 animais por tratamento foram amostrados em 3 períodos: 2, 4 e 8 dias pós-tratamento (DPT). Foram coletadas amostras de sangue para determinação do hemograma e avaliação do bioquímico sérico, além de órgãos como baço, fígado e rins (cranial e caudal) para avaliação somática e histopatológica. Os resultados não mostraram diferença significativa entre os tratamentos nos valores séricos de creatinina, proteína total, colesterol, triglicerídeos, globulina, glicemia e atividade da enzima fosfatase alcalina. No entanto, os níveis séricos de AST (aspartato aminotransferase) foram significativamente maiores (P<0,05) nos animais tratados com 80 mg de doxiciclina no período mais longo de tratamento (8 dias). Na avaliação hematológica de tilápias tratadas com doxiciclina, não foram observadas alterações significativas (P>0,05) nas contagens de eritrocitos, valores de hematocrito, VCM, HCM e CHCM. Tilápias tratadas com doxiciclina não apresentaram diferença significativa na análise somática do baço, fígado e rim quando comparadas aos animais do grupo controle. Portanto, os resultados demonstraram a segurança clínica do tratamento oral com doxiciclina nas doses de 10, 20, 40 e 80 mg/kg de peso corporal, embora alterações transitórias na funcionalidade hepática tenham sido observadas após oito dias de tratamento com a dose de 80mg/kg.

Effect of dietary supplementation with astaxanthin on the hematological and biochemical response of nile tilapia (Oreochromis niloticus) / Efeito da suplementação alimentar com astaxantina na resposta hematológica e bioquímica de tilápias do nilo (Oreochromis niloticus)

This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.

Objetivou-se avaliar o efeito da astaxantina na resposta hematológica, bioquímica e somática de tilápias do Nilo (Oreochromis niloticus) administrada via oral na ração por período de 60 dias. Para o estudo foram utilizadas 105 tilápias (n=35) oriundas da mesma desova, constituindo os seguintes tratamentos: Controle = animais (não tratados com astaxantina); T100= Animais tratados com 100mg de astaxantina/kg de ração; T200= Animais tratados com 200mg astaxantina/kg de ração. Não se observou alterações hematológicas na série vermelha (glóbulos vermelhos, hematócrito, hemoglobina, VCM e CHCM), além disso, apresentou melhor resposta trombocitária e leucocitária com marcada diminuição no número de linfócitos e neutrófilos. Não ocorreu alterações nos níveis séricos de proteína total, albumina, globulinas, aspartate aminotransferase e fostatase alcalina. O tratamento com astaxantina resultou em diminuição nos níveis de triglicerídeos, glicose e aumento nos índices hepatossomáticos. Portanto, os resultados das análises hematológicas e bioquímicas das tilápias demonstraram a segurança clínica desse carotenóide, não causando efeitos nocivos à saúde dos peixes. No entanto, a atividade antioxidante desse composto em tilápias resultou em melhora do perfil leucocitário e contribuiu para efeitos hipolipemiantes na dose de 200mg de astaxantina / kg de ração.

Effect of dietary supplementation with astaxanthin on the hematological and biochemical response of nile tilapia (Oreochromis niloticus) / Efeito da suplementação alimentar com astaxantina na resposta hematológica e bioquímica de tilápias do nilo (Oreochromis niloticus)

This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.(AU)

Objetivou-se avaliar o efeito da astaxantina na resposta hematológica, bioquímica e somática de tilápias do Nilo (Oreochromis niloticus) administrada via oral na ração por período de 60 dias. Para o estudo foram utilizadas 105 tilápias (n=35) oriundas da mesma desova, constituindo os seguintes tratamentos: Controle = animais (não tratados com astaxantina); T100= Animais tratados com 100mg de astaxantina/kg de ração; T200= Animais tratados com 200mg astaxantina/kg de ração. Não se observou alterações hematológicas na série vermelha (glóbulos vermelhos, hematócrito, hemoglobina, VCM e CHCM), além disso, apresentou melhor resposta trombocitária e leucocitária com marcada diminuição no número de linfócitos e neutrófilos. Não ocorreu alterações nos níveis séricos de proteína total, albumina, globulinas, aspartate aminotransferase e fostatase alcalina. O tratamento com astaxantina resultou em diminuição nos níveis de triglicerídeos, glicose e aumento nos índices hepatossomáticos. Portanto, os resultados das análises hematológicas e bioquímicas das tilápias demonstraram a segurança clínica desse carotenóide, não causando efeitos nocivos à saúde dos peixes. No entanto, a atividade antioxidante desse composto em tilápias resultou em melhora do perfil leucocitário e contribuiu para efeitos hipolipemiantes na dose de 200mg de astaxantina / kg de ração.(AU)

Abiotrofia cerebelar em um gato: relato de caso / Cerebellar abiotrophy in a feline: case report

Um caso de abiotrofia cerebelar em um gato com 45 dias de idade foi diagnosticado no Laboratório de Patologia Animal, Hospital Veterinário da Universidade Federal de Campina Grande. O animal apresentava, havia 15 dias, apatia, anorexia, desidratação, ataxia, hipermetria, espasticidade dos membros torácicos e pélvicos, tremores de intenção, nistagmo, opistótono, déficit proprioceptivo e ausência de resposta de ameaça. Clinicamente, havia a suspeita de hipoplasia cerebelar, e, devido ao prognóstico desfavorável, o animal foi eutanasiado. Na necropsia, não foram observadas alterações macroscópicas. Microscopicamente, as lesões estavam restritas ao cerebelo e caracterizavam-se por alterações neurodegenerativas e necróticas, com desaparecimento segmentar dos neurônios de Purkinje. Nessas áreas, também se verificaram espaços em branco, denominado aspecto de cesto vazio, resultantes da perda dos neurônios de Purkinje, além de raros esferoides axonais e proliferação dos astrócitos de Bergmann. Em algumas áreas, a camada granular estava hipocelular e havia moderada gliose multifocal na camada molecular. O diagnóstico de abiotrofia cerebelar foi realizado com base nos dados epidemiológicos, clínicos e, principalmente, pelas alterações histopatológicas dos neurônios de Purkinje características da doença.(AU)

The aim of this report was to describe a case of cerebellar abiotrophy in cat with 45-year-old diagnosed at the Animal Pathology Laboratory, Veterinary Hospital of the Federal University of Campina Grande. The animal had presented 15-day apathy, anorexia, dehydration and neurological signs, characterized by ataxia, hypermetria, spasticity of fore and hindlimbs, intention tremor, nystagmus, opisthotonos, proprioceptive deficits, and absence of threat response. Clinically, cerebellar hypoplasia was suspected and the animal was euthanized due to poor prognosis. During necropsy, gross lesions were not observed. Microscopically the lesions were restricted to the cerebellum and were characterized by neurodegenerative and necrotic damage with segmental disappearance of the Purkinje cells. In these areas, there were also empty spaces, called the empty basket aspect, resulting from the loss of Purkinje cells, as well as rare axonal spheroids and proliferation of Bergmann's astrocytes. In some areas, the granular layer was hypocellular and there was moderate multifocal gliosis in the molecular layer. The diagnosis of cerebellar abiotrophy was based on epidemiological, clinical and mainly on histopathological changes in neurons of Purkinje disease characteristics.(AU)

Abiotrofia cerebelar em um gato: relato de caso / Cerebellar abiotrophy in a feline: case report

Um caso de abiotrofia cerebelar em um gato com 45 dias de idade foi diagnosticado no Laboratório de Patologia Animal, Hospital Veterinário da Universidade Federal de Campina Grande. O animal apresentava, havia 15 dias, apatia, anorexia, desidratação, ataxia, hipermetria, espasticidade dos membros torácicos e pélvicos, tremores de intenção, nistagmo, opistótono, déficit proprioceptivo e ausência de resposta de ameaça. Clinicamente, havia a suspeita de hipoplasia cerebelar, e, devido ao prognóstico desfavorável, o animal foi eutanasiado. Na necropsia, não foram observadas alterações macroscópicas. Microscopicamente, as lesões estavam restritas ao cerebelo e caracterizavam-se por alterações neurodegenerativas e necróticas, com desaparecimento segmentar dos neurônios de Purkinje. Nessas áreas, também se verificaram espaços em branco, denominado aspecto de cesto vazio, resultantes da perda dos neurônios de Purkinje, além de raros esferoides axonais e proliferação dos astrócitos de Bergmann. Em algumas áreas, a camada granular estava hipocelular e havia moderada gliose multifocal na camada molecular. O diagnóstico de abiotrofia cerebelar foi realizado com base nos dados epidemiológicos, clínicos e, principalmente, pelas alterações histopatológicas dos neurônios de Purkinje características da doença.(AU)

The aim of this report was to describe a case of cerebellar abiotrophy in cat with 45-year-old diagnosed at the Animal Pathology Laboratory, Veterinary Hospital of the Federal University of Campina Grande. The animal had presented 15-day apathy, anorexia, dehydration and neurological signs, characterized by ataxia, hypermetria, spasticity of fore and hindlimbs, intention tremor, nystagmus, opisthotonos, proprioceptive deficits, and absence of threat response. Clinically, cerebellar hypoplasia was suspected and the animal was euthanized due to poor prognosis. During necropsy, gross lesions were not observed. Microscopically the lesions were restricted to the cerebellum and were characterized by neurodegenerative and necrotic damage with segmental disappearance of the Purkinje cells. In these areas, there were also empty spaces, called the empty basket aspect, resulting from the loss of Purkinje cells, as well as rare axonal spheroids and proliferation of Bergmann's astrocytes. In some areas, the granular layer was hypocellular and there was moderate multifocal gliosis in the molecular layer. The diagnosis of cerebellar abiotrophy was based on epidemiological, clinical and mainly on histopathological changes in neurons of Purkinje disease characteristics.(AU)

Seasonal influence on biochemical profile and serum protein electrophoresis for Boa constrictor amarali in captivity / Influência sazonal sobre o perfil bioquímico e a eletroforese de proteínas séricas de Boa constrictor amarali criada em cativeiro

Similarly to other reptiles, snakes are ectothermic animals and depend exclusively on the environment for the maintenance of their physiological, biochemical and immunological processes. Thus, changes in biochemical values can be expected due to seasonal influence. Twenty-two adult specimens of Boa constrictor amarali kept in captivity were used. Blood collections were done in two different seasons: winter (July 2004) and summer (January 2005) for the following assays: uric acid, aspartate aminotransferase (AST), glucose, cholesterol, total protein, and serum protein electrophoresis. The mean biochemical results found in summer and winter, respectively, were: 6.3 ± 3.4 and 11.3 ± 6.2 mg/dL for uric acid; 28.7 ± 12.4 and 20.7 ± 16.2 UI/L for AST; 26.3 ± 17 and 17.4 ± 6.8 mg/dL for glucose; 67.3 ± 30.2 and 69.7 ± 38.5 mg/dL for cholesterol; and 5.9 ± 1.6 and 5.9 ± 1.4 g/dL for total protein. Results regarding electrophoresis in summer and winter, respectively, were: 1.9 ± 0.7 and 2.4 ± 0.6 g/dL for albumin; 0.7 ± 0.2 and 0.5 ± 0.2 g/dL for α-globulin; 1.5 ± 0.5 and 1.7 ± 0.6 g/dL for β-globulin; and 1.8 ± 0.5 and 1.5 ± 0.5 g/dL for g-globulin. In the summer, there was a significant increase in AST and a decrease in uric acid (p < 0.05). Serum protein electrophoresis showed a significant increase in α-globulin fraction (p < 0.05) in the same season. There were not significant differences between seasons for the remaining variables. Based on these results, the period of the year must be considered in the interpretation of some biochemical values for these animals.(AU)

As serpentes, como outros répteis, são animais ectotérmicos e dependem exclusivamente do meio para a manutenção de seus processos fisiológicos, bioquímicos e imunológicos. Desta forma, alterações nos valores bioquímicos podem ser esperadas considerando-se a influência sazonal. Foram utilizadas vinte e duas Boa constrictor amarali adultas mantidas em cativeiro. A coleta de sangue foi realizada em duas estações diferentes: inverno (julho 2004) e verão (Janeiro 2005), para a realização dos exames: ácido úrico, aspartato aminotransferase (AST), glicose, colesterol, proteína total e eletroforese da proteína sérica. As médias dos exames bioquímicos obtidos no verão e inverno, respectivamente, foram: 6.3 ± 3.4 e 11.3 ± 6.2 mg/dL para ácido úrico; 28.7 ± 12.4 e 20.7 ± 16.2 UI/L para AST; 26.3 ± 17 e 17.4 ± 6.8 mg/dL para glicose; 67.3 ± 30.2 e 69.7 ± 38.5 mg/dL para colesterol; e 5.9 ± 1.6 e 5.9 ± 1.4 g/dL para proteína total. Os resultados da eletroforese no verão e inverno, respectivamente, foram: 1.9 ± 0.7 e 2.4 ± 0.6 g/dL para albumina; 0.7 ± 0.2 e 0.5 ± 0.2 g/dL para α globulina; 1.5 ± 0.5 e 1.7 ± 0.6 g/dL β globulina; e 1.8 ± 0.5 e 1.5 ± 0.5 g/dL para g globulina. No verão foi observado aumento significativo da AST (p < 0,05) e diminuição significativa do ácido úrico (p < 0,05). Na eletroforese de proteína sérica, houve um aumento significativo da fração a globulina (p < 0,05) na mesma estação. Para as outras variáveis não foram obtidas diferenças significativas entre as estações. De acordo com os resultados, é importante considerar o período do ano na interpretação de alguns exames bioquímicos desses animais.(AU)

Toad poisoning in three dogs: case reports

Toad poisoning is frequent in dogs, but has been infrequently addressed in published case reports and review articles. Dogs can be poisoned when they bite a toad or otherwise ingest the venom. The venom effects manifest soon after the accident, since the toxin is rapidly absorbed by the mucous membrane of the digestive system. Hospital records of three dogs, diagnosed with toad poisoning, were retrospectively reviewed from January 2005 to July 2007. Poisoned dogs may present only local irritation or systemic signs in the gastrointestinal, cardiac and neurological systems. All three cases presented herein had clinical signs of gastrointestinal alterations including vomiting, sialorrhea and diarrhea. Two dogs developed abnormal cardiac rhythm and two exhibited neurological signs. A poisoned animal requires emergency care and symptomatic therapy with intense monitoring of its clinical parameters. Although there have been reports on the low mortality of dogs poisoned by toads, one animal died even after appropriate therapy. The severity of clinical signs and the risk of death must be considered by the veterinarian.(AU)

EFFECT OF DIETARY SUPPLEMENTATION WITH ASTAXANTHIN ON THE HEMATOLOGICAL AND BIOCHEMICAL RESPONSE OF NILE TILAPIA (Oreochromis niloticus)

This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed.